



Date: 29th July, 2025

The Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001

The Secretary
The Calcutta Stock Exchange Limited
7, Lyon Range
Kolkata - 700001

Dear Sir/Madam,

Sub: Copies of un-audited financial results for the quarter ended 30.06.2025
Published in the newspapers

Please find the enclosed copies of un-audited financial results for the quarter ended 30.06.2025 published in the newspaper "Financial Express" - English Edition and "Jan Satta" - Hindi Edition approved by the Board of Directors in their meeting held on 28.07.2025.

Please take note of the same.

Thanking you,
For Aravali Securities and Finance Limited


Ruchi Shrivastava
Company Secretary



Encl:A/a

ARAVALI SECURITIES & FINANCE LIMITED

REGD. OFFICE : RIDER HOUSE, Ground Floor, Plot No. 136, Sector-44, Gurgaon-122003

Phone : +91-124-4284578/4284580/4284582

CIN : L67120HR1980PLC039125 | Website: www.aravalisecurities.com | Email : info@aravalisecurities.com

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES NOR IT IS A PROSPECTUS ANNOUNCEMENT **NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA.**
INITIAL PUBLIC OFFERING OF EQUITY SHARES OF THE COMPANY ON THE MAIN BOARD OF THE BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE") AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") IN COMPLIANCE WITH CHAPTER II OF THE SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED ("SEBI ICDR REGULATIONS")

PUBLIC ANNOUNCEMENT



(Please scan this QR Code to view the DRHP)

nephroplus

NEPHROCARE HEALTH SERVICES LIMITED

Our Company was incorporated as "Nephrocare Health Services Private Limited", a private limited company under the Companies Act, 1956, at Hyderabad with a certificate of incorporation issued by the Assistant Registrar of Companies, Andhra Pradesh ("RoC Andhra Pradesh") on December 18, 2009. Pursuant to resolutions dated April 11, 2025 and June 2, 2025 passed by our Board and Shareholders, respectively, our Company was converted into a public limited company and consequently, the name of our Company was changed to "Nephrocare Health Services Limited" with a fresh certificate of incorporation dated June 18, 2025 issued by the Registrar of Companies, Central Registration Centre. See "History and Certain Corporate Matters - Changes in the Registered Office" on page 316 of the draft red herring prospectus dated July 25, 2025 ("DRHP").

Registered and Corporate Office: 5th Floor, D Block, iLabs Centre, Plot 18, Software Units Layout, Survey No. 64, Madhapur, Shaikpet, Hyderabad 500 081, Telangana, India
Contact Person: Kishore Kathri, Company Secretary and Compliance Officer; Tel: +91 40 4240 8038, E-mail: cs@nephroplus.com; Website: www.nephroplus.com;
Corporate Identity Number: U85160TG2009PLC066359

PROMOTERS OF OUR COMPANY: VIKRAM VUPPALA, BESSEMER VENTURE PARTNERS TRUST, EDORAS INVESTMENT HOLDINGS PTE. LTD., HEALTHCARE PARENT LIMITED, INVESTCORP PRIVATE EQUITY FUND II AND INVESTCORP GROWTH OPPORTUNITY FUND

INITIAL PUBLIC OFFERING OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("EQUITY SHARES") OF NEPHROCARE HEALTH SERVICES LIMITED ("OUR COMPANY" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE FACE VALUE OF ₹2 (INCLUDING A SECURITIES PREMIUM OF ₹[●] PER EQUITY SHARE) ("OFFER PRICE") AGGREGATING UP TO ₹[●] MILLION ("OFFER") COMPRISING A FRESH ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹3,534.05 MILLION ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 12,792,056 EQUITY SHARES OF FACE VALUE OF ₹2 EACH ("OFFERED SHARES") AGGREGATING UP TO ₹[●] MILLION, COMPRISING AN OFFER FOR SALE OF UP TO 1,680,360 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INVESTCORP PRIVATE EQUITY FUND II AND UP TO 1,813,140 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY HEALTHCARE PARENT LIMITED AND UP TO 147,765 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INVESTCORP GROWTH OPPORTUNITY FUND AND UP TO 4,081,000 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY EDORAS INVESTMENT HOLDINGS PTE. LTD. ("PROMOTER SELLING SHAREHOLDERS") AND UP TO 121,985 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INVESTCORP INDIA PRIVATE EQUITY OPPORTUNITY LIMITED AND UP TO 3,089,663 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY INTERNATIONAL FINANCE CORPORATION AND UP TO 1,433,468 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 9 AND UP TO 444,675 EQUITY SHARES OF FACE VALUE OF ₹2 EACH AGGREGATING UP TO ₹[●] MILLION BY 360 ONE SPECIAL OPPORTUNITIES FUND - SERIES 10 ("OTHER SELLING SHAREHOLDERS") AND TOGETHER WITH THE PROMOTER SELLING SHAREHOLDERS, THE "SELLING SHAREHOLDERS" AND SUCH OFFER FOR SALE BY THE SELLING SHAREHOLDERS, THE "OFFER FOR SALE". THE OFFER SHALL CONSTITUTE [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE OFFER INCLUDES A RESERVATION OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹2 EACH, AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL), FOR SUBSCRIPTION BY ELIGIBLE EMPLOYEES ("EMPLOYEE RESERVATION PORTION"). THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE "NET OFFER". THE OFFER AND THE NET OFFER SHALL CONSTITUTE [●]% AND [●]% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY, RESPECTIVELY. OUR COMPANY MAY IN CONSULTATION WITH THE BRLMS, OFFER A DISCOUNT OF ₹[●] ON THE ISSUE PRICE TO ELIGIBLE EMPLOYEES BIDDING IN THE EMPLOYEE RESERVATION PORTION ("EMPLOYEE DISCOUNT").

THE FACE VALUE OF THE EQUITY SHARES IS ₹2 EACH. THE OFFER PRICE IS [●] TIMES THE FACE VALUE OF THE EQUITY SHARES. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BOOK RUNNING LEAD MANAGERS, AND WILL BE ADVERTISED IN ALL EDITIONS OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER), ALL EDITIONS OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND [●] EDITIONS OF [●] (A WIDELY CIRCULATED TELUGU DAILY NEWSPAPER, TELUGU BEING THE REGIONAL LANGUAGE OF TELANGANA, WHERE OUR REGISTERED OFFICE IS LOCATED) AT LEAST TWO WORKING DAYS PRIOR TO THE BID/OFFER OPENING DATE IN ACCORDANCE WITH THE SEBI ICDR REGULATIONS AND SUCH ADVERTISEMENT SHALL BE MADE AVAILABLE TO BSE LIMITED ("BSE") AND NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE"), AND TOGETHER WITH BSE, THE "STOCK EXCHANGES") FOR UPLOADING ON THEIR RESPECTIVE WEBSITES.

OUR COMPANY, IN CONSULTATION WITH THE BRLMS, MAY CONSIDER A FURTHER ISSUE OF SPECIFIED SECURITIES (I.E., FULLY PAID-UP PREFERENCE SHARES AND/OR EQUITY SHARES) TO CERTAIN INVESTORS FOR AN AMOUNT AGGREGATING UP TO ₹706.51 MILLION ("PRE-IPO PLACEMENT"), AS PERMITTED UNDER APPLICABLE LAWS ON OR PRIOR TO THE DATE OF FILING OF THE RED HERRING PROSPECTUS WITH THE ROC. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, WILL BE AT A PRICE TO BE DECIDED BY OUR COMPANY, IN CONSULTATION WITH THE BRLMS. IF THE PRE-IPO PLACEMENT IS COMPLETED, THE AMOUNT RAISED PURSUANT TO THE PRE-IPO PLACEMENT WILL BE REDUCED FROM THE FRESH ISSUE, SUBJECT TO COMPLIANCE WITH RULE 19(2)(B) OF THE SCRR. THE PRE-IPO PLACEMENT, IF UNDERTAKEN, SHALL NOT EXCEED 20% OF THE SIZE OF THE FRESH ISSUE. PRIOR TO THE COMPLETION OF THE OFFER, OUR COMPANY SHALL APPROPRIATELY INTIMATE THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT. PRIOR TO ALLOTMENT PURSUANT TO THE PRE-IPO PLACEMENT, THAT THERE IS NO GUARANTEE THAT OUR COMPANY MAY PROCEED WITH THE OFFER OR THE OFFER MAY BE SUCCESSFUL AND WILL RESULT INTO LISTING OF THE EQUITY SHARES ON THE STOCK EXCHANGES. FURTHER, RELEVANT DISCLOSURES IN RELATION TO SUCH INTIMATION TO THE SUBSCRIBERS TO THE PRE-IPO PLACEMENT (IF UNDERTAKEN) SHALL BE APPROPRIATELY MADE IN THE RELEVANT SECTIONS OF THE RED HERRING PROSPECTUS AND PROSPECTUS.

In case of any revision in the Price Band, the Bid/ Offer Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of one Working Day, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a public notice and also by indicating the change on the websites of the BRLMs and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank(s), as applicable.

The Offer is being made in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR"), read with Regulation 31 of the SEBI ICDR Regulations. The Offer is being made through the Book Building Process in compliance with Regulation 6(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to QIBs (the "QIB Portion"), provided that our Company, in consultation with the BRLMs, may allocate up to 60% of the QIB Portion to Anchor Investors and the basis of such allocation will be on a discretionary basis by our Company, in consultation with the BRLMs, in accordance with the SEBI ICDR Regulations (the "Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors ("Anchor Investor Allocation Price"). In the event of under-subscription or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the remaining QIB Portion (other than Anchor Investor Portion) ("Net QIB Portion"). Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, subject to valid Bids being received at or above the Offer Price, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not less than 15% of the Net Offer shall be available for allocation to NITs ("Non-Institutional Category") of which one-third of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹200,000 and up to ₹1,000,000 and two-thirds of the Non-Institutional Category shall be available for allocation to Bidders with an application size of more than ₹1,000,000 and under-subscription in either of these two sub-categories of Non-Institutional Category may be allocated to Bidders in the other sub-category of Non-Institutional Category in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. Further, not less than 35% of the Net Offer shall be available for allocation to RILs ("Retail Category"), in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. All Bidders, other than the Anchor Investors, shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount ("ASBA") process, providing details of their respective bank accounts (including UPI ID (defined hereinafter)) for UPI Bidders (defined hereinafter) in which the Bid amount will be blocked by the Self Certified Syndicate Banks ("SCSBs") or the Sponsor Bank(s) under the UPI Mechanism, as the case may be, to the extent of the respective Bid Amounts. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. For further details, see "Offer Procedure" beginning on page 523 of the DRHP.

This public announcement is being made in compliance with the provisions of Regulation 26(2) of the SEBI ICDR Regulations to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its Equity Shares pursuant to the Offer and has filed the DRHP dated July 25, 2025 with the SEBI and with the Stock Exchanges on July 26, 2025. Pursuant to Regulation 26(1) of the SEBI ICDR Regulations, the DRHP filed with SEBI and Stock Exchanges shall be made available to the public for comments, if any, for period of at least 21 days, from the date of publication of this public announcement, by hosting it on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e., BSE at www.bseindia.com and NSE at www.nseindia.com, respectively, on the website of the Company at www.nephroplus.com and the websites of the BRLMs, i.e., ICICI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) and Nomura Financial Advisory and Securities (India) Private Limited at www.icicisecurities.com, www.ambit.co, www.iiflcap.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Our Company hereby invites the public to provide comments on the DRHP filed with SEBI and the Stock Exchanges with respect to disclosures made therein. The public are requested to send a copy of the comments to either: SEBI, to the Company Secretary and Compliance Officer of our Company and/or the BRLMs and the Registrar to the Issue at their respective addresses mentioned below. All comments must be received by our Company and/or the BRLMs and/or the Registrar to the Issuer and/or the Company Secretary and Compliance Officer of our Company on or before 5:00 p.m. on the 21st day from the date of publication of this public announcement.

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Bidders are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, Bidders must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares of face value of ₹2 each have not been recommended or approved by the SEBI, nor does SEBI guarantee the accuracy or adequacy of the contents of the Draft Red Herring Prospectus. Specific attention of the Bidders is invited to "Risk Factors" beginning on page 43 of the DRHP.

Any decision to invest in the Equity Shares described in the DRHP may only be made after the Red Herring Prospectus ("RHP") and must be made solely on the basis of such RHP that shall be filed with the RoC as there may be material changes in the RHP from the DRHP.

The Equity Shares, when offered, through the RHP, are proposed to be listed on BSE and NSE. For details of the main objects of the Company as contained in its Memorandum of Association, see "History and Certain Corporate Matters" on page 316 of the DRHP. The liability of the members of the Company is limited by shares. For details of the share capital and capital structure of the Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of the Company see "Capital Structure" on page 114 of the DRHP.

BOOK RUNNING LEAD MANAGERS				REGISTRAR TO THE ISSUE
ICICI Securities	AMBIT Account at work	IIFL CAPITAL	NOMURA	KFINTTECH
ICICI Securities Limited ICICI Venture House Appasaheb Marathe Marg, Prabhadevi Mumbai 400 025 Tel: +91 22 6807 7100 E-mail: nephroplus ipo@icicisecurities.com Website: www.icicisecurities.com Contact Person: Aboli Pitre / Namrata Ravasla Investor Grievance ID: customercare@icicisecurities.com SEBI Registration No.: INM000011179	Ambit Private Limited Ambit House, 448 Senapati Bapat Marg Lower Parel Mumbai 400 013 Maharashtra, India Tel: + 91 22 6623 3030 E-mail: nephroplus ipo@ambit.co Website: www.ambit.co Contact Person: Siddhesh Deshmukh/ Arundhati Iyer Investor grievance e-mail: customer.service@ambit.co SEBI Registration No: INM000010585	IIFL Capital Services Limited (formerly known as IIFL Securities Limited) 24 th Floor, One Lodha Place Senapati Bapat Marg, Lower Parel (West), Mumbai 400 013 Maharashtra, India Tel: + 91 22 4646 4728 E-mail: nephroplus ipo@iiflcap.com Website: www.iiflcap.com Contact Person: Yogesh Malpani / Pawan Kumar Jain Investor grievance e-mail: ig_ib@iiflcap.com SEBI Registration No.: INM000010940	Nomura Financial Advisory and Securities (India) Private Limited Geeljay House, Level 11 Plot F, Shivsagar Estate Dr. Annie Besant Road, Worli Mumbai 400 016, Maharashtra, India Tel: +91 22 4037 4037 E-mail: nephroplus ipo@nomura.com Website: www.nomuraholdings.com/ company/group/asia/india/index.html Contact Person: Vishal Kanjani / Chirag Shah Investor grievance e-mail: investorgrievances-in@nomura.com SEBI Registration No: INM000011419	KFin Technologies Limited Selenium, Tower B, Plot No - 31 and 32 Financial District, Nanakramguda Serlingampally, Hyderabad 500 032 Telangana, India Tel: +91 40 6716 2222 E-mail: nephroplus ipo@kfintech.com Website: www.kfintech.com Contact Person: M Murali Krishna Investor grievance email: enward.ms@kfintech.com SEBI Registration Number: INR000000221

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

For NEPHROCARE HEALTH SERVICES LIMITED
On behalf of the Board of Directors
Sd/
Kishore Kathri
Company Secretary and Compliance Officer

Place: Hyderabad, Telangana
Date: July 26, 2025

NEPHROCARE HEALTH SERVICES LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on July 26, 2025. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, and is available on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of the Company at www.nephroplus.com and the websites of the BRLMs, i.e., ICICI Securities Limited, Ambit Private Limited, IIFL Capital Services Limited (formerly known as IIFL Securities Limited) and Nomura Financial Advisory and Securities (India) Private Limited at www.icicisecurities.com, www.ambit.co, www.iiflcap.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" beginning on page 43 of the DRHP. Potential investors should not rely on the DRHP filed with SEBI and the Stock Exchanges, and should instead rely on their own examination of our Company and the Offer, including the risks involved, for making any investment decision.

The Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in "offshore transactions" in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdictions where such offers and sales are made. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

Adattam 30/7/25



अरावली सिक्योरिटीज एंड फाइनेंस लिमिटेड

सीआईएन - 1671201HR1980PLC039125

पंजीकृत कार्यालय प्लॉट नं. 138, गुरु, गडहरी रोड, सेक्टर 44, तुंगुगुड-122003, हरियाणा,
ईमेल: info@aravalsecurities.com, वेबसाइट: www.aravalsecurities.com

30 जून, 2025 को समाप्त तिमाही के लिए स्टैंडअलोन अलेक्सापरीक्षित वित्तीय परिणामों के कथन

क्र.सं.	विवरण	समाप्त तिमाही		समाप्त वर्ष
		30.06.2025 अलेक्सापरीक्षित	30.06.2024 अलेक्सापरीक्षित	31.03.2025 अलेक्सापरीक्षित
1	कुल आय	23.58	23.12	20.70
2	कर से पहले की अवधि के लिए शुद्ध लाभ(हानि) (कर से पहले, अमवादात्मक और ध्या असाधारण मदों से पहले)	(6.87)	(9.57)	(12.67)
3	कर से पहले की अवधि के लिए शुद्ध लाभ(हानि) (अमवादात्मक और /या असाधारण मदों के बाद)	(6.87)	(9.57)	(12.67)
4	कर के बाद की अवधि के लिए शुद्ध लाभ(हानि) (अमवादात्मक और /या असाधारण मदों के बाद)	(6.87)	(9.05)	(12.67)
5	अवधि के लिए कुल व्यापक आय [अवधि (कर के बाद) के लिए संयुक्त लाभ(हानि) और अन्य व्यापक आय (कर के बाद)]	(6.74)	(9.35)	(12.54)
6	इक्विटी शेयर पूंजी	1515.38	1515.38	1515.38
7	आरक्षित (पिछले वर्ष के लेखा-परीक्षित तुलन पत्र में दिखाए गए अनुसार पुनर्मूल्यांकन आरक्षितों को छोड़कर)			(1607.73)
8	प्रति शेयर आय(रु. 10/- प्रत्येक का) द्वैसक डाइकट	Rs (0.04) Rs (0.04)	Rs (0.06) Rs (0.06)	Rs (0.08) Rs (0.08)

- टिप्पणी:**
- उपरोक्त विवरण सेबी (सूचीबद्धता दायित्व और प्रकटीकरण आवश्यकताएं) विनियम, 2015 के विनियमन 33 के तहत स्टॉक एक्सचेंजों के साथ दायर 31 मार्च, 2025 को समाप्त तिमाही और वर्ष के लिए अलेक्सापरीक्षित वित्तीय परिणामों के विस्तृत प्रारूप का उद्घरण है। अलेक्सापरीक्षित का पूर्ण प्रारूप वित्तीय परिणाम और ईएसई लिमिटेड की वेबसाइट (www.bseindia.com) पर उपलब्ध है जहां कंपनी की प्रतिकृति सूचीबद्ध है और कंपनी की वेबसाइट www.aravalsecurities.com पर उपलब्ध है।
 - उपरोक्त वित्तीय परिणाम कंपनी अधिनियम, 2013 ("अधिनियम") की धारा 133 के तहत निर्धारित भारतीय लेखा मानकों ("इंड एस") के अनुसार तैयार किए गए हैं, जो इंड एस में निर्धारित मान्यता और माप सिद्धांतों को ध्यान में रखते हैं। 34 ("अंतरिम वित्तीय रिपोर्टिंग") और अन्य मान्यता प्राप्त लेखांकन प्रथाएं जो आम तौर पर भारत में स्वीकार की जाती हैं और सेबी (सूचीबद्धता दायित्व एवं प्रकटीकरण आवश्यकताएं) विनियम, 2015 ("सूचीबद्धता विनियम") के विनियमन 33 के अनुपालन में हैं।
 - 30 जून, 2025 को समाप्त तिमाही के लिए कंपनी के उपरोक्त अलेक्सापरीक्षित परिणामों की समीक्षा अलेक्सापरीक्षा समिति द्वारा की गई है और 28 जुलाई, 2025 को आयोजित बैठक में निदेशक मंडल द्वारा अनुमोदित किया गया है।
 - कंपनी के वित्तीय लेखा परीक्षकों ने 30 जून, 2025 को समाप्त तिमाही के लिए कंपनी के उपर्युक्त अलेक्सापरीक्षित वित्तीय परिणामों की सीमित समीक्षा की है और उसी पर अवशोषित राय दी है।
 - आयकर अधिनियम, 1961 के तहत करधान का प्रकाशन समूची वर्ष के लिए अनुमानित कर योग्य आय के आधार पर किया गया है।
 - वर्तमान में कंपनी का परिचालन केवल एक खंड तक ही सीमित है यानी वित्तीय एवं अन्य सलाहकार सेवाएं प्रदान करना और तदनुसार इंड एस 108-ऑपरेटिंग सेगमेंट के अनुसार कोई अलग रिपोर्ट करने योग्य ऑपरेटिंग सेगमेंट नहीं है।
 - 31 मार्च, 2025 को समाप्त तिमाही के आंकड़े 31 मार्च, 2025 को समाप्त वर्ष के संबंध में अलेक्सापरीक्षित आंकड़ों और प्रासंगिक वित्तीय वर्ष के 31 दिसंबर 2024 को समाप्त तीसरी तिमाही तक प्रकाशित वर्ष के आंकड़ों के बीच अंतर वाले संतुलनकारी आंकड़े हैं।
 - पिछली तिमाही/वर्ष के आंकड़ों को तुलनीय बनाने के लिए, जब भी आवश्यक हुआ, पुन: समूहीकरण/पुनर्व्यवस्था किया गया है।



बोर्ड के आदेशानुसार
कृते अरावली सिक्योरिटीज एंड फाइनेंस लिमिटेड
हस्ता /—
रंजन कुमार पोद्दार
अध्यक्ष एवं प्रबंध निदेशक

दिनांक: 28 जुलाई, 2025
स्थान: तुंगुगुड



इंटरग्लोब एविएशन लिमिटेड

सीआईएन: एल62100डीएल2004पीएलसी129768

पंजीकृत कार्यालय: अपर ग्राऊंड प्लोर, थापर हाउस, गेट नं. 2,

वेस्टर्न विंग, 124 जनपथ, नई दिल्ली-110001, भारत

टेलीफोन: +91 9650098905; फैक्स: +91 11 43513200

ई-मेल: investors@goindigo.in; वेबसाइट: www.goindigo.in

22वीं वार्षिक आम बैठक और रिमोट ई-वोटिंग जानकारी की सूचना

एतद्वारा सूचित किया जाता है कि इंटरग्लोब एविएशन लिमिटेड ("कंपनी") के सदस्यों की 22वीं वार्षिक आम बैठक ("एजीएम") बुधवार, 20 अगस्त, 2025 को 11:00 बजे (आईएसटी) वीडियो कॉन्फ्रेंसिंग/अन्य ऑडियो-विडियो माध्यमों ("वीसी/ओवीएम") के द्वारा आयोजित की जाएगी। कॉर्पोरेट कार्य मंत्रालय परिपत्र सं. 09/2024 दिनांक 19 सितंबर, 2024 और भारतीय प्रतिभूति तथा विनियम बोर्ड ("सेबी") परिपत्र सं. सेबी/एसओ/सीएफडी/सीएफडी-पीओडी-2/पी/सीआईआर/2024/133 दिनांक 3 अक्टूबर, 2024 के अनुपालन में कंपनियों को सदस्यों की आम स्थल पर भौतिक उपस्थिति के बिना वीसी/ओवीएम के माध्यम से एजीएम आयोजित करने की अनुमति है। इसलिए एजीएम में निर्धारित कामकाज के निष्पादन के लिए कंपनी की एजीएम वीसी/ओवीएम के माध्यम से आयोजित की जा रही है।

उपयुक्त परिपत्रों के अनुसार एजीएम की सूचना और वित्त वर्ष 25 की वार्षिक रिपोर्ट की इलेक्ट्रॉनिक प्रतियां उन सभी सदस्यों को भेज दी गई हैं, जिनके ईमेल पते कंपनी/डिपॉजिटरी प्रतिभागी(यों) के पास फंजीकृत हैं। इसके अतिरिक्त, सेबी (सूचीबद्धता दायित्व और प्रकटीकरण आवश्यकताएं) विनियम, 2015 के नियमन 36(1)(बी) के अनुसार कंपनी ने उन सदस्यों को भी पत्र भेजे हैं जिनके ईमेल पते डिपॉजिटरी/कंपनी के पास फंजीकृत नहीं हैं जिनमें वित्त वर्ष 25 की वार्षिक रिपोर्ट और कंपनी की एजीएम की सूचना एक्सेस करने के लिए वेब-लॉक उपलब्ध कराया गया है। एजीएम की सूचना और वार्षिक रिपोर्ट कंपनी की वेबसाइट www.goindigo.in पर निवेशक संबंध अनुभाग के अंतर्गत, स्टॉक एक्सचेंजों की वेबसाइटों अर्थात् बीएसई लिमिटेड की वेबसाइट www.bseindia.com और नेशनल स्टॉक एक्सचेंज ऑफ इंडिया लिमिटेड की वेबसाइट www.nseindia.com पर तथा एनएसडीएल की वेबसाइट <http://www.evoting.nsdl.com> पर भी उपलब्ध है।

कट-ऑफ तिथि अर्थात् 13 अगस्त, 2025 के अनुसार फिजिकल या डिमेंटियरियालाइज्ड प्रारूप में शेयर रखने वाले सदस्यगण रिमोट ई-वोटिंग या एजीएम के दौरान ई-वोटिंग के माध्यम से अपना वोट डाल सकते हैं। एजीएम में शामिल होने के निर्देश और रिमोट ई-वोटिंग या एजीएम के दौरान ई-वोटिंग के माध्यम से वोट डालने की प्रक्रिया सूचना में दी गई है।

सभी सदस्यों को सूचित किया जाता है कि:

- एजीएम की सूचना में निर्धारित कामकाज रिमोट ई-वोटिंग या एजीएम में ई-वोटिंग के माध्यम से किया जा सकता है।
- रिमोट ई-वोटिंग या एजीएम में ई-वोटिंग द्वारा वोटिंग की पात्रता निर्धारित करने की कट-ऑफ तिथि 13 अगस्त, 2025 होगी।
- रिमोट ई-वोटिंग शुक्रवार, 15 अगस्त, 2025 को 09:00 बजे (आईएसटी) प्रारंभ होगी और मंगलवार, 19 अगस्त, 2025 को 17:00 बजे (आईएसटी) समाप्त होगी। उपरोक्त तिथि और समय के बाद रिमोट ई-वोटिंग की अनुमति नहीं होगी। एक बार किसी सदस्य द्वारा प्रस्ताव पर वोट देने के बाद सदस्य को बाद में इसे बदलने की अनुमति नहीं होगी।
- कोई भी व्यक्ति जो एजीएम की सूचना भेजे जाने के बाद कंपनी के शेयर अधिग्रहित करता है और कंपनी का सदस्य बनता है तथा कट-ऑफ तिथि अर्थात् 13 अगस्त, 2025 तक शेयर धारण करता है वह [evoting.nsdl.com](http://www.evoting.nsdl.com) पर अनुरोध भेजकर लॉगिन आईडी और पासवर्ड प्राप्त कर सकता है। हालांकि, यदि वह रिमोट ई-वोटिंग के लिए पहले से ही एनएसडीएल के साथ फंजीकृत है, तो वह वोट डालने के लिए अपने मौजूदा यूजर आईडी और पासवर्ड का उपयोग कर सकता है।
- एजीएम के दौरान ई-वोटिंग की सुविधा भी उपलब्ध कराई जाएगी और वीसी सुविधा के माध्यम से एजीएम में उपस्थित ऐसे सदस्यगण जिन्होंने रिमोट ई-वोटिंग के माध्यम से प्रस्तावों पर अपना वोट नहीं डाला है और अन्यथा ऐसा करने से प्रतिबंधित नहीं है केवल वे ही एजीएम के दौरान ई-वोटिंग के माध्यम से वोट करने के पात्र होंगे।
- जिन सदस्यों ने पहले रिमोट ई-वोटिंग के माध्यम से अपना वोट डाला है, वे एजीएम में उपस्थित हो सकते हैं लेकिन उन्हें दोबारा वोट डालने का अधिकार नहीं होगा।
- केवल वे व्यक्ति जिनका नाम कट-ऑफ तिथि के अनुसार सदस्यों के रजिस्टर या डिपॉजिटरीज द्वारा तैयार किए गए लाभार्थी स्वामियों के रजिस्टर में दर्ज है केवल वे ही रिमोट ई-वोटिंग या एजीएम में ई-वोटिंग की सुविधा का लाभ उठाते हैं हकदार होंगे।
- डिमेंट मोड में शेयर रखने वाले और जिन्होंने अपना ईमेल पता या कंवांसीस विवरण फंजीकृत/अपडेट नहीं किया है उनसे अनुरोध है कि वे अपने डिपॉजिटरी प्रतिभागी(यों) के माध्यम से अपनी डिपॉजिटरीज के पास अपना ईमेल आईडी या कंवांसीस विवरण फंजीकृत/अपडेट करें।
- ई-वोटिंग से संबंधित प्रश्नों के मामले में सदस्यगण एनएसडीएल की वेबसाइट के डाउनलोड सेक्शन में अक्सर पूछे जाने वाले प्रश्न (एफएक्यू) और ई-वोटिंग यूजर मैन्युअल को देख सकते हैं या टोल-फ्री नं. 022 - 4886 7000 पर कॉल कर सकते हैं या पलटवी म्हात्रे, वरिष्ठ प्रबंधक, एनएसडीएल से evoting@nsdl.com; पता - तीसरा तल, नमन चैंबर, प्लॉट सी-32, जी-ब्लॉक, बांद्रा कुर्ला कॉम्प्लेक्स, बांद्रा पूर्व, मुंबई, महाराष्ट्र - 400051 पर संपर्क कर सकते हैं।
- वित्त वर्ष 25 के लिए अंतिम लाभार्थी हेतु सदस्यों की पात्रता निर्धारित करने की रिकॉर्ड तिथि बुधवार, 13 अगस्त, 2025 होगी। एजीएम में सदस्यों के अनुमोदन के अधीन लाभार्थी का भुगतान सदस्यों के अनुमोदन की तिथि से 30 दिनों के भीतर किया जाएगा।

इंटरग्लोब एविएशन लिमिटेड के लिए

हस्ता/—
दिनांक: 28 जुलाई, 2025
स्थान: गुरुग्राम
कंपनी सचिव तथा मुख्य अनुपाल अधिकारी